Adage Capital Partners’s Ocular Therapeutix OCUL Stock Holding History

Adage Capital Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.2M	Buy	+1,550,000	New	+$14M	0.02%	593
2026 Q1	–	Sell	-4,625,050	Closed	-$56.1M	–	1041
2025 Q4	$56.1M	Buy	4,625,050 +620,700	+16%	+$7.54M	0.09%	227
2025 Q3	$46.8M	Buy	4,004,350 +114,173	+3%	+$1.37M	0.07%	251
2025 Q2	$36.1M	Sell	3,890,177 -1,309,823	-25%	-$10.3M	0.06%	306
2025 Q1	$38.1M	Buy	5,200,000 +1,600,000	+44%	+$12.3M	0.07%	288
2024 Q4	$30.7M	Sell	3,600,000 -150,000	-4%	-$1.46M	0.05%	320
2024 Q3	$32.6M	Buy	3,750,000 +54,953	+1%	+$453K	0.06%	318
2024 Q2	$25.3M	Buy	3,695,047 +3,320,047	+885%	+$20.5M	0.05%	376
2024 Q1	$3.41M	Buy	+375,000	New	+$2.66M	0.01%	737

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's OCUL Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 1,550,000 shares worth $15.2M. The stake represents 0.02% of the portfolio and ranks #593 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in OCUL as recently as Q4 2025.

Adage Capital Partners first reported a position in OCUL in Q1 2024 and has held it in 9 quarters since. The position peaked at $56.1M in Q4 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Adage Capital Partners held 1,550,000 shares of Ocular Therapeutix worth $15.2M as of Q2 2026.
Ocular Therapeutix was a new Adage Capital Partners position in Q2 2026.
Ocular Therapeutix made up 0.02% of Adage Capital Partners's portfolio in Q2 2026, its #593 holding.
Adage Capital Partners first reported a position in Ocular Therapeutix in Q1 2024 and has held it in 9 quarters since.
Adage Capital Partners's Ocular Therapeutix position peaked at $56.1M in Q4 2025.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.